AEON Biopharma (AEON) director awarded 222,684 RSUs in equity grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

FISCHER JOST reported acquisition or exercise transactions in this Form 4 filing.

AEON Biopharma director Jost Fischer received an equity grant in the form of restricted stock units. The award covers 222,684 RSUs granted on June 17, 2026 at no cash cost, increasing his direct holdings to 489,469 shares of Class A Common Stock.

The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the date of AEON Biopharma’s 2027 annual meeting of stockholders, conditioned on his continued service through the applicable vesting date. This is a compensation-related grant rather than an open‑market share purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FISCHER JOST

Role null

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	222,684	$0.00	--

Holdings After Transaction: Class A Common Stock — 489,469 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 222,684 RSUs Grant price: $0.0000 per share Holdings after grant: 489,469 shares +1 more

4 metrics

RSU grant size 222,684 RSUs Granted on June 17, 2026 as equity award

Grant price $0.0000 per share RSU award with no cash paid by director

Holdings after grant 489,469 shares Class A Common Stock directly owned after transaction

Grant date June 17, 2026 Date RSU award was granted

Key Terms

restricted stock units ("RSUs"), vest in full, annual meeting of the Company's stockholders, continued service

4 terms

restricted stock units ("RSUs") financial

"Represents an award of restricted stock units ("RSUs") granted on June 17, 2026"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vest in full financial

"The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary"

annual meeting of the Company's stockholders financial

"and (ii) the date of the 2027 annual meeting of the Company's stockholders"

continued service financial

"subject to continued service through the applicable vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 06:20 PM Accepted by SEC EDGAR 06/22/2026 - 06:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FISCHER JOST

(Last)

(First)

(Middle)

C/O AEON BIOPHARMA, INC.

5 PARK PLAZA, SUITE 1750

(Street)

IRVINE

CALIFORNIA

92614

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AEON Biopharma, Inc. [ AEON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock⁽¹⁾	06/17/2026		A		222,684	A	$0⁽¹⁾	489,469	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

	/s/ Alexander Wilson, as Attorney-in-Fact, for Jost Fischer	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did AEON (AEON) director Jost Fischer report in this Form 4?

Director Jost Fischer reported receiving 222,684 restricted stock units from AEON Biopharma as a compensation grant. These RSUs were issued at no cash cost and are scheduled to vest in full based on time and service conditions tied to 2027.

How many AEON Biopharma (AEON) RSUs were granted to Jost Fischer?

Jost Fischer was granted 222,684 restricted stock units of AEON Biopharma Class A Common Stock. This is a single equity award reported as an acquisition, reflecting compensation rather than an open-market transaction, and will convert into shares only after vesting conditions are met.

What is the vesting schedule for Jost Fischer’s AEON (AEON) RSUs?

The RSUs vest in full on the earlier of the one-year anniversary of June 17, 2026 or the date of AEON Biopharma’s 2027 annual stockholders’ meeting. Vesting requires Mr. Fischer to remain in service through the applicable vesting date to receive the underlying shares.

Did Jost Fischer pay cash for the AEON Biopharma (AEON) RSU grant?

No, the RSU grant was recorded at a price of $0.0000 per share, indicating no cash payment by Jost Fischer. Such grants are typical equity compensation awards, with economic value realized only if and when the RSUs vest into actual shares.

What are Jost Fischer’s AEON (AEON) holdings after this RSU grant?

Following the RSU award, Jost Fischer’s direct holdings are reported as 489,469 shares of AEON Biopharma Class A Common Stock. This figure reflects his position after the June 17, 2026 grant and shows his ongoing equity stake aligned with the company’s performance.

Is this AEON (AEON) Form 4 a buy or a compensation grant?

This Form 4 reflects a compensation-related acquisition rather than an open-market stock purchase. The transaction is coded as a grant or award of RSUs, emphasizing equity-based director compensation that vests over time instead of immediate trading activity in AEON Biopharma shares.